

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-167 (cancelled).

168 (currently amended). A method of effecting ~~change in the surface antigens~~ expressed by incorporating a synthetic molecule construct of the structure F-S<sub>1</sub>-S<sub>2</sub>-L into the lipid bi-layer of a cell or a multi-cellular structure ~~comprising including the step~~ of:

of contacting a suspension of the cell or multi-cellular structure with a the synthetic molecule construct of the structure ~~F-S<sub>1</sub>-S<sub>2</sub>-L~~ for a time and at a temperature sufficient to effect the change; allow incorporation where:


F is a glycoepitope mono-, di-, tri- or oligo- saccharide;

S<sub>1</sub> is a C<sub>3-5</sub>-aminoalkyl selected from the group consisting of: 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl;

S<sub>2</sub> is selected from the group consisting of: -CO(CH<sub>2</sub>)<sub>2</sub>CO-, -CO(CH<sub>2</sub>)<sub>3</sub>CO-, -CO(CH<sub>2</sub>)<sub>4</sub>CO- (adipate) and or -CO(CH<sub>2</sub>)<sub>5</sub>CO-; and

L is a lipid selected from the group consisting of diacyl- and or dialkyl-glycerophospholipids.

169 (currently amended). The method according to claim 168 where the construct includes the substructure:



where:

$n = 3$  to  $5$ , and  $M$  is  $H$  or a monovalent cation selected from the group consisting of  $Na^+$ ,  $K^+$  or  $NH_4^+$ , and  $*$  is other than  $H$ .

170 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is of human or murine origin.

171 (previously presented). The method according to claim 168 where the concentration of the construct in the suspension is in the range  $0.1$  to  $10$  mg/mL.

172 (previously presented). The method according to 168 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range  $2$  to  $37$  °C.

173 (previously presented). The method according to claim 172 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range  $2$  to  $25$  °C.

174 (previously presented). The method according claim 173 where the suspension of the cell or multi-cellular structure is contacted with the construct at a

temperature in the range 2 to 4 °C.

175 (previously presented). The method according to claim 168 where F is selected from the group consisting of GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ ; Gal $\alpha$ 1-3Gal $\beta$ ; Gal $\beta$ ; Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ ; NeuAc $\alpha$ 2-3Gal $\beta$ ; NeuAc $\alpha$ 2-6Gal $\beta$ ; Fuc $\alpha$ 1-2Gal $\beta$ ; Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(Gal $\beta$ 1-4GlcNAc $\beta$ 1-3)Gal $\beta$ ; Fuc $\alpha$ 1-2Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(Fuc $\alpha$ 1-2Gal $\beta$ 1-4GlcNAc $\beta$ 1-3)Gal $\beta$ ; Fuc $\alpha$ 1-2Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(NeuAc $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc $\beta$ 1-3)Gal $\beta$ ; NeuAc $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc $\beta$ 1-6(NeuAc $\alpha$ 2-3Gal $\beta$ 1-4GlcNAc $\beta$ 1-3)Gal $\beta$ ; Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc; GalNAc $\beta$ 1-3Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc; GalNAc $\alpha$ 1-3GalNAc $\beta$ 1-3Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc; and GalNAc $\beta$ 1-3GalNAc $\beta$ 1-3Gal $\alpha$ 1-4Gal $\beta$ 1-4Glc.


176 (currently amended). The method according to claim 175 where F is selected from the group consisting of the oligosaccharides GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$  and Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ .

177 (previously presented). The method according to claim 168 where S<sub>1</sub> is 3-aminopropyl.

178 (previously presented). The method according to claim 168 where L is selected from the group consisting of: 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE).

179 (withdrawn—currently amended). The method according to claim 168


where the construct is:



designated A<sub>tri</sub>-sp-Ad-DOPE (I).


180 (withdrawn—currently amended). The method according to claim 168

where the construct is:



designated A<sub>tri</sub>-sp-Ad-DSPE (III).


181 (withdrawn—currently amended). The method according to claim 168  
 where the construct is:



designated B<sub>tri</sub>-sp-Ad-DOPE (VI).


182 (withdrawn—currently amended). The method according to claim 168


where the construct is:



designated H<sub>tri</sub>-sp-Ad-DOPE (VII).


183 (withdrawn—currently amended). The method according to claim 168  
 where the construct is:






designated H<sub>dl</sub>-sp-Ad-DOPE (VIII).

184 (withdrawn). The method according to claim 168 where the construct is:




designated Gal $\beta$ -sp-Ad-DOPE (IX).

185 (withdrawn—currently amended). The method according to claim 168 where the construct is:









designated  $\text{Fuca}1\text{-}2\text{Gal}\beta 1\text{-}3\text{GlcNAc}\beta 1\text{-}3\text{Gal}\beta 1\text{-}4\text{GlcNAc-sp-Ad-DOPE}$  (XII).

186 (withdrawn—currently amended). The method according to claim 168  
 where the construct is:





designated Fuca1-2Galβ1-3(Fuca1-4)GlcNAc-sp-Ad-DOPE (XIII).

187 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is a red blood cell.

188-189 (cancelled).